Extended Data Fig. 1: The mutational landscape and clinical parameters CLPD-NK patients. | Nature Genetics

Extended Data Fig. 1: The mutational landscape and clinical parameters CLPD-NK patients.

From: CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk

Extended Data Fig. 1

a, Heatmap of the 59 cases with CLPD-NK in the discovery cohort and 62 CLPD-NK cases in the validation cohort. CCL22 mutations were detected in 16 out of 59 (27%) and 10 out of 62 (16%) cases and were mutually exclusive of STAT3 mutations. Higher CD56 expression was observed in CCL22 mutant cases. b,c, Distribution of CD56 and CD16 expression in the discovery cohort. Hb, hemoglobin; Plt, platelet; WBC, white blood cell; yr, year.

Back to article page